ArticleThe journal of physiological sciences : JPS2026
Jinshui Liujun Decoction attenuates cigarette smoke-induced small airway remodeling via the TGF-β/Smad2/CFTR Axis.
Article in The journal of physiological sciences : JPS, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Small airway remodeling is a key pathological feature of chronic obstructive pulmonary disease (COPD), and epithelialmesenchymal transition (EMT) is among the central mechanisms driving this remodeling process. Jinshui Liujun Decoction (JSLJD), a traditional Chinese herbal formula, has shown therapeutic potential in respiratory diseases, but its effects on COPD-associated small airway remodeling remain unclear. In this study, JSLJD significantly reduced collagen accumulation, airway wall thickening, and α-SMA expression in the lungs of cigarette smoke (CS)-exposed mice. In vivo and in vitro, JSLJD inhibited EMT, as reflected by elevated E-cadherin expression and reduced vimentin, fibronectin, and Snail expression. Mechanistically, JSLJD inhibited TGF-β/Smad2 activation and restored cystic fibrosis transmembrane conductance regulator (CFTR) expression. Pharmacological blockade of CFTR or activation of TGF-β abrogated the anti-EMT effects of JSLJD. In conclusion, JSLJD alleviates CS-induced small airway remodeling by suppressing EMT via the inhibition of the TGF-β/Smad2 pathway and the recovery of CFTR function, highlighting its promise as a prospective therapy for COPD.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.